NetworkNewsBreaks

ThursdaySep 22, 2016 1:55 pm

MagneGas Corporation (MNGA) Hits Corporate Milestone with Construction of Gasification System

MagneGas (NASDAQ: MNGA) this morning announced that it has completed construction of the Plasma-Arc Gasification system – a move company CEO Ermanno Santilli calls “the single most important event of the year.” Under the previously announced “Gasifier Agreement,” Green Arc Supply, LLC is contracted to purchase the system and thus far has paid a total of $583,750 toward construction of the system. Upon final payment of $191,500, expected in the next 30 days pending factory acceptance, Green Arc will have exclusive distribution rights to MagneGas2® for certain regions of Louisiana and Texas, as well as non-exclusive distribution rights in remaining…

Continue Reading

WednesdaySep 21, 2016 2:02 pm

Peregrine Pharmaceuticals, Inc. (PPHM, PPHMP) Issues Update on Presentation of Top-Line Data at European Society for Medical Oncology

Peregrine Pharmaceuticals (NASDAQ: PPHM, PPHMP) reports that it will present top-line data from the phase 3 SUNRISE trial of its bavituximab cancer treatment as a late-breaking oral presentation at the upcoming European Society for Medical Oncology (ESMO) 2016 Congress. The company will present data showing that a biomarker in the SUNRISE trial correlated with a statistically significant improvement in overall survival for patients treated with bavituximab in combination with docetaxel compared to patients treated with docetaxel alone. Peregrine will file a new patent application directed to the use of the biomarker prior to the presentation of results at the ESMO…

Continue Reading

WednesdaySep 21, 2016 1:58 pm

Xplore Technologies Corp. (XPLR) Successfully Completes Compatibility Testing of XSLATE D10 Fully Rugged Tablet

Xplore Technologies (NASDAQ: XPLR) has completed the MobileIron Android Self Testing Program, confirming that its XSLATE D10 fully rugged tablet PC is compatible with Android for Work in MobileIron’s (NASDAQ: MOBL) mobile device management (MDM) environment. The testing program is designed for manufacturers to verify whether their devices support the Google standard APIs, which are used by MobileIron to enable password policies, encryption, certificate management and other enterprise features. To view the full press release, visit: http://nnw.fm/3nW4h About Xplore Technologies Corp. Xplore is The Rugged Tablet Authority, exclusively manufacturing powerful, long-lasting, and customer-defined rugged tablet PCs since 1996. Today, Xplore…

Continue Reading

WednesdaySep 21, 2016 1:54 pm

Skyline Medical, Inc. (SKLN) Partners with GLG Pharma to Develop Oncology Test Panels

Skyline Medical (NASDAQ: SKLN), producer of the FDA-approved STREAMWAY System for automated, direct-to-drain medical fluid disposal, has entered into an exclusive reseller agreement in which GLG Pharma, LLC intends to develop rapid diagnostic tests that utilize fluid and tissue collected by the STREAMWAY System during procedures. Per the agreement, Skyline will issue common stock to GLG Pharma in four separate tranches, with each tranche released after the achievement of certain development milestones. In addition, Skyline will pay a royalty to GLG on the sale of individual tests. To view the full press release, visit: http://nnw.fm/CgH4x About Skyline Medical, Inc. Skyline…

Continue Reading

WednesdaySep 21, 2016 1:50 pm

Eleven Biotherapeutics, Inc.’s (EBIO) Acquisition of Viventia Bio Creates Targeted Protein Therapeutics Oncology Company

Through a share purchase agreement, Eleven Biotherapeutics, Inc. (NASDAQ: EBIO) has acquired Viventia Bio, Inc., creating a single entity focused on the development of novel treatments in areas of oncology with significant unmet need. In addition to other drug candidates, Eleven’s pipeline now includes Viventias’ two lead product candidates: Vicinium, in a phase 3 clinical trial for high-grade non-muscle invasive bladder cancer (NMIBC), with topline data expected in the first half of 2018; and Proxinium, expected to enter phase 2 development in early 2017 for the treatment of late-stage squamous cell carcinoma of the head and neck. To view the…

Continue Reading

WednesdaySep 21, 2016 1:44 pm

AmeriCann, Inc. (ACAN) Launches New Line of Cannabis-Infused Products

AmeriCann (OTCQX: ACAN), developer of the proposed Massachusetts Medical Cannabis Center (MMCC) cultivation and processing facility, today unveiled its latest line of nutraceutical-grade cannabis-infused products. AmeriCann will license the intellectual property behind “Solanna” to regulated cannabis businesses looking to offer healthier alternatives to smoking, including capsules, topical lotions and balms, sublingual tinctures, oral dissolving film, trans-dermal applications, and oil cartridges for vaporizing. The company says it intends to later expand the product line to include edible products, health drinks, and branded concentrates offered at varying dosages. To view the full press release, visit: http://nnw.fm/lUwH6 About AmeriCann, Inc. AmeriCann is a…

Continue Reading

WednesdaySep 21, 2016 7:46 am

LM Funding America, Inc. (LMFA) Capitalizing on Growing U.S. Debt Collection Industry

According to data from the U.S. Federal Reserve Board (http://nnw.fm/dPEg3), roughly $3.66 trillion in consumer credit was outstanding in the United States as of July 2016. About 90 percent of these accounts are expected to be repaid pursuant to the terms of the contractual agreement, according to DBA International (http://nnw.fm/I4pf2). The remaining 10 percent, however, serve as the foundation for the massive debt collection industry, which returned approximately $44.6 billion to creditors in 2010, according to PricewaterhouseCoopers. One company operating in this lucrative industry is LM Funding America, Inc. (NASDAQ: LMFA), a specialty financing company that offers funding to nonprofit…

Continue Reading

WednesdaySep 21, 2016 7:43 am

BioLineRx Ltd. (BLRX) Initiates Phase 2a Trial for Pancreatic Cancer Therapy

BioLineRx Ltd. (NASDAQ: BLRX) announced that it has initiated a Phase 2a trial investigating BL-8040 in combination with KEYTRUDA (pembrolizumab), MSD's anti-PD-1 therapy, in patients with metastatic pancreatic cancer. The study is designed to evaluate the safety and efficacy of the combination of BL-8040 and KEYTRUDA in up to 30 subjects with metastatic pancreatic adenocarcinoma. The study is designed to evaluate the clinical response, safety and tolerability of the combination of these therapies as well as multiple pharmacodynamic parameters, including the ability to improve infiltration of T cells into the tumor and their reactivity. To view the full press release,…

Continue Reading

WednesdaySep 21, 2016 7:40 am

Airgain, Inc. (AIRG) Announces Q2 2016 Financial Results

Airgain, Inc. (NASDAQ : AIRG) today reported results for the second quarter ended June 30, 2016. Sales increased 63% to $9.9 million year over year, gross profit increased 79% to $4.5 million year over year, total operating expenses increased 31% year over year, and net income attributable to common stockholders totaled $700,428 versus a loss of $781,689 a year ago. Other key metrics include a 62% increase in total customer devises to 12 million, a 24% increase in the average number of antennas per device, and a 1% decrease in the average selling price per device. To view the full…

Continue Reading